ClinicalTrials.gg
RecruitingNCT07259538Updated Dec 2, 2025

A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray

A Phase 1 interventional study of 0.5% VVN432 Nasal Spray and 1% VVN432 Nasal Spray in Chronic Rhinosinusitis (CRS), sponsored by VivaVision Biotech, Inc. Recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by VivaVision Biotech, Inc · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Rhinosinusitis with a site in China — 18 open to participants now, 25 under way, 7 of them phase 3. Rhinosinusitis · China.

Planned enrollment
30th of 36
60 · median 117
Started
2025
with 9 others
Phase 1
Only one
of the 40
Primary completion
2026-07
later than 7 of 24 live
Registered
30th of 40
by date

Among the 40 studies in Rhinosinusitis with a site in China, this one is the 30th largest by planned enrollment of the 36 interventional ones that give a count, is one of 10 that started in 2025, is the only one in phase 1, reaches primary completion later than 7 of the 24 other live ones, and was the 30th registered.

Rhinosinusitis

252 studies on the registry are indexed under Rhinosinusitis; 70 are open to participants now.

Browse Rhinosinusitis studies →

Open to participants now

18 of the 40 studies in Rhinosinusitis with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 34 Rhinosinusitis studies recruiting now, 15 (44%) set no upper age limit and 13 (38%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Rhinosinusitis with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VVN432 Nasal Spray in healthy volunteers (Phase Ia) and in patients with chronic rhinosinusitis (Phase 1b).

This study consists of two parts (Phase 1a and Phase 1b):

Phase 1a (SAD) is a single-center, randomized, double-masked, vehicle-controlled study to assess the safety, tolerability, and PK of VVN432 Nasal Spray in healthy adult subjects.

Phase 1b (MAD) is a multi-center, randomized, double-masked, vehicle-controlled study to assess the safety, tolerability, PK/PD, and preliminary efficacy of VVN432 Nasal Spray in patients with chronic rhinosinusitis.

03

Conditions studied

  • Chronic Rhinosinusitis (CRS)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part 1:

  • Healthy male or female subjects aged 18 to 55 years old (inclusive);
  • Body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females; (BMI) within the range of 18.5 to 28.0 kg/m2 (inclusive);
  • No abnormalities at screening or baseline.

Part 2:

  • Male or female patients aged 18 to 55 years old (inclusive);
  • Clinically confirmed diagnosis of chronic rhinosinusitis with or without nasal polyps;
  • Presence of the following symptoms for >4 weeks before screening: nasal obstruction, mucous or mucopurulent rhinorrhea, facial pain/pressure, and reduced or lost sense of smell;
  • Modified Lund-Kennedy (MLK) score ≥ 2 in each nostril by nasal endoscopy;
  • Lund-Mackay score (LMK) ≥ 2 in each nostril by CT scan;
  • Nasal Construction Score (NCS) ≥ 2.

Exclusion criteria

Exclusion Criteria:

Part 1:

  • Known or to the study drug or its components;
  • History or current conditions that affect the safety or absorption of the drug;
  • History of drug abuse or drug dependence;
  • Participation in any other clinical trials and receiving an investigational drug within 12 weeks before screening or 5 half-lives, whichever is longer;
  • If female, is pregnant or lactating, or intends to become pregnant during the study period.

Part 2:

  • Known hypersensitivity or contraindications to the study drug or its components;
  • Use of prohibited medications prior to screening and during the course of the study; History of drug abuse or drug dependence;
  • Participation in any other clinical trials and receiving an investigational drug within 12 weeks before screening or 5 half-lives, whichever is longer;
  • If female, is pregnant or lactating, or intends to become pregnant during the study period.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Part 1: 0.5% VVN432 Nasal Spray (1 spray/nostril)

    0.5% VVN432 Nasal Spray, single dose, 1 spray/nostril

    Drug: 0.5% VVN432 Nasal Spray

  • Experimental
    Part 1: 1% VVN432 Nasal Spray (1 spray/nostril)

    1% VVN432 Nasal Spray, single dose, 1 spray/nostril

    Drug: 1% VVN432 Nasal Spray

  • Experimental
    Part 1: 1% VVN432 Nasal Spray (2 spray/nostril)

    1% VVN432 Nasal Spray, single dose, 2 sprays/nostril

    Drug: 1% VVN432 Nasal Spray

  • Placebo comparator
    Part 1: Vehicle

    VVN432 Nasal Spray Placebo, single dose, 1 or 2 sprays/nostril

    Drug: Vehicle

  • Experimental
    Part 2: 0.5% VVN432 Nasal Spray (1 spray/nostril)

    0.5% VVN432 Nasal Spray, BID, 1 spray/nostril, for 28 days

    Drug: 0.5% VVN432 Nasal Spray

  • Experimental
    Part 2: 1% VVN432 Nasal Spray (1 spray/nostril)

    1% VVN432 Nasal Spray, BID, 1 spray/nostril, for 28 days

    Drug: 1% VVN432 Nasal Spray

  • Experimental
    Part 2: 1% VVN432 Nasal Spray (2 sprays/nostril)

    1% VVN432 Nasal Spray, BID, 2 sprays/nostril, for 28 days

    Drug: 1% VVN432 Nasal Spray

  • Placebo comparator
    Part 2: Vehicle

    VVN432 Nasal Spray Placebo, BID, 1 or 2 sprays/nostril, for 28 days

    Drug: Vehicle

Interventions

  • Drug0.5% VVN432 Nasal Spray

    0.5% VVN432 Nasal Spray

  • Drug1% VVN432 Nasal Spray

    1% VVN432 Nasal Spray

  • DrugVehicle

    VVN432 Nasal Spray, Placebo

06

What researchers measure

Primary outcomes

  1. Part 1: To evaluate the safety and tolerability of VVN432 Nasal Spray.

    Incidence of the AEs and SAEs; change from baseline in laboratory tests, ECG, and vital signs

    Time frame: Baseline to Day 10

  2. Part 2: To evaluate the safety and tolerability of VVN432 Nasal Spray

    Incidence of the AEs and SAEs; change from baseline in laboratory tests, ECT, and vital signs

    Time frame: Baseline to Day 35

Secondary outcomes

  1. Part 1: To evaluate the systemic PK of VVN432 Nasal Spray

    Plasma concentration of VVN432, and assess the PK parameters if applicable

    Time frame: 48 hours

  2. Part 1: To evaluate the local PK of VVN432 Nasal Spray

    Local concentration of VVN432 in the eluent of oropharyngeal swabs and nasal swabs, and in nasal lavage fluid post-dose

    Time frame: 48 hours

  3. Part 2: To evaluate the systemic PK of VVN432 Nasal Spray

    Plasma concentration of VVN432, and assess the PK parameters if applicable

    Time frame: Day 1, Day 28, and Day 35

  4. Part 2: To evaluate the local PK of VVN432 Nasal Spray

    Local concentration of VVN432 in the eluent of nasal swabs post-dose

    Time frame: Day 1, Day 28, and Day 35

  5. Part 2: Efficacy: Nasal Congestion Score (NCS)

    Change from baseline in NCS (0-3, higher scores indicate more severe symptoms)

    Time frame: Baseline to Day 35

  6. Part 2: Efficacy: Total Symptom Score (TSS)

    Change from Baseline in TSS (0-9 \[sum of NCS, loss of smell, and average of anterior and posterior rhinorrhea\], higher scores indicate more severe symptoms)

    Time frame: Baseline to Day 35

07

Study locations

1 of 1 sites recruiting
  • Beijing Toren Hospital
    Beijing, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Jul 2026, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2025
First posted
Dec 2, 2025
StartActual
Nov 6, 2025
Primary completionEst.
Jul 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07259538
Lead sponsor
VivaVision Biotech, Inc
Responsible party
Sponsor
First posted
Dec 2, 2025
Start date
Nov 6, 2025
Primary completion
Jul 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Dec 2, 2025

Study contacts

Caroline Lu
Contact
caroline.lu@vivavisionbio.com
86-18816562189

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion